Oppenheimer Maintains Outperform on Evolent Health, Raises Price Target to $7
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $6 to $7.
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $6 to $7.